MétaCan
Menu
Back to cohort
Record W4405044069 · doi:10.1182/blood-2024-203020

Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort

2024· article· en· W4405044069 on OpenAlexaffabout
Chrystelle Charles, Olena Bereznyakova, Grégory Jacquin, J. A. Colin Bergeron, Amer Yassine Hafsaoui, Valérie Fraïle, Nancy Van Synghel, Anais Elodie Arethuse, Costa Kazadi, Sara-Maude Desforges, Olivier Pouliot, Philippe Desmarais, Christian Stapf, Stéphanie Forté

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldMedicine
TopicHemoglobinopathies and Related Disorders
Canadian institutionsInstitut Universitaire de Gériatrie de MontréalCentre Hospitalier de l’Université de MontréalUniversité de Montréal
Fundersnot available
KeywordsMedicineCohortSickle cell anemiaDiseaseInternal medicinePediatrics

Abstract

fetched live from OpenAlex

Background Individuals with sickle cell disease (SCD) are at a high risk of symptomatic stroke, vascular brain lesions, and cognitive impairment. Although these neurovascular complications are well documented in children, data in contemporary cohorts of adults remain limited. In addition, the effect of disease modifying interventions on the outcome of neurovascular complications over the lifespan are unknown. Since 2021, a multidisciplinary neurology-hematology clinic has been established at the Centre Hospitalier de l'Université de Montréal (CHUM). The primary aim of this study is to describe the study entry prevalence of symptomatic stroke and of any cognitive impairment in the Montreal-Brain-SCD cohort. The secondary aim is to measure the effect of the specialized clinic on diagnosis of cognitive comorbidities. Methods This prospective study is conducted at the CHUM with the ultimate goal of creating a database of all patients followed as part of the Montréal-Brain-SCD cohort. We present the baseline characteristics at study inclusion. The local ethics committee approved the project and patients signed informed consent. Participants, aged ≥18 of all genotypes (HbSS, HbS β°/β+-thalassemia, HbSC), were included if they had ≥1 visit between September 2021 and June 2024. Symptomatic stroke was defined as any cerebral infarction or intracranial hemorrhage on brain imaging with a corresponding focal neurological deficit or symptomatology. The diagnosis of cognitive disorder (major and mild) was defined according to the International Society of Vascular Behavioral and Cognitive Disorders (VasCog). Attention disorder broadly included difficulties with attention and formal diagnosis of attention deficit disorder (ADD). Findings A total of 292 adults with SCD were included. The median age was 32 years (18-79), 167 (57%) were female. The genotype distribution was 142 (48%) individuals with the SS/Sβ0 genotype, 122 (42%) of the SC genotype, and 28 (10%) of the Sβ+. Overall, 182 patients (62%) received hydroxyurea treatment, while 58 (20%) were on chronic transfusions. Both therapies were administered concurrently to 17 patients (6%). Prior to the first assessment at the specialized clinic, the prevalences were: 12 patients (4%) had a confirmed history of prior stroke during their lifetime, 4 (1%) had a diagnosis of major cognitive disorder (MCD), none of mild cognitive disorder and 15 (5%) of ADD. After a first visit at the clinic, the number of confirmed cases of MCD increased significantly from 4 (1%) to 15 (5%) (Fisher exact test, p-value <0.001), with one patient in whom the diagnosis was revised from MCD to intellectual deficiency. Mild cognitive disorder was diagnosed in 17 (6%). Before the assessment, attention disorder was diagnosed in 15 (5%). However, after further assessment, 8 diagnoses were retracted, with one modified to mild cognitive disorder, and 33 new diagnoses were made. As a result, a significantly higher proportion of patients had a diagnosis of attention disorder (40, 14%) (χ2 = 11.746, p-value < 0.001). The prevalence of confirmed stroke increased with age, with 0/109 (0%) in the 18-29 age group, 3/89 (3%) in the 30-39 age group, 5/51 (10%) in the 40-49 age group, 2/31 (7%) in the 50-59 age group and 2/12 (17%) in the ≥60 age group. The prevalence of MCD also increased with age, with 9/280 (3%) in the 18-59 age groups and 6/12 (50%) in the ≥60 age group. However, the overall prevalence of attention disorder in the cohort decreased with age, with 18/109 (17%) in the 18-29 age group, 11/89 (12%) in the 30-39 age group, 9/51 (18%) in the 40-49 age group, 2/31 (7%) in the 50-59 age group and 0/12 (0%) in the ≥60 age group. Our analyses revealed a significant association between prior stroke and any diagnosis of cognitive disorder (Fisher exact test, p-value = 0.001). Interpretation This study carried out in an adult cohort of SCD patients revealed a high proportion of stroke and cognitive disorders. These results underline the need for a thorough neurological assessment in individuals with SCD, revealing an initial underdiagnosis of cognitive and attentional disorders. This highlights the neurocognitive vulnerability of this population, notably in those with a previous stroke. A prospective study of neurological complications affecting adult patients with SCD is ongoing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.354
Threshold uncertainty score0.703

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.223
Teacher spread0.218 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBloodSame topicHemoglobinopathies and Related DisordersFrench-language works237,207